NEW YORK (GenomeWeb News) – Cenix BioScience said today that it has agreed to help Regulus Therapeutics develop its miRNA modulators for immunology and inflammation therapeutics.
Under the research agreement, Cenix said it will use multi-parametric assays to screen Regulus’ libraries of synthetic miRNA modulators for novel molecules that could be used to develop new therapeutics. Specifically, Cenix said that it will apply its small RNA-based gene silencing technology with high-content phenotypic analyses in cultured human cells.
Regulus is a California-based company that was founded in 2007 as a joint effort between Alnylam Pharmaceuticals and Isis Pharmaceuticals.
Cenix offers research and consulting services using human and rodent cell models to discover, validate, and analyze new drug targets for a variety of diseases including atherosclerosis, diabetes, obesity, malaria, and others.
Financial terms of the agreement were not released.